The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of ...

Apr 30, 2025 · Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase …

Nov 27, 2025 · Explore the current issue of The New England Journal of Medicine (Vol. 393 No. 21).

Dec 11, 2024 · Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the …

Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell …

Apr 23, 2025 · In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl …

Nov 20, 2024 · Bloodstream infections are associated with substantial morbidity and mortality. Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain. In …

Feb 7, 2025 · Methods In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose …

Jun 1, 2025 · Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate …

Mar 31, 2025 · Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial …